rs587784441
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PM4PP3PP5_Very_Strong
The NM_001130438.3(SPTAN1):c.6908_6916dupACCAGCTGG(p.Asp2303_Leu2305dup) variant causes a disruptive inframe insertion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001130438.3 disruptive_inframe_insertion
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Developmental and epileptic encephalopathy, 5 Pathogenic:6
A Heterozygous Inframe indel variant c.6881_6882insGGACCAGCT in Exon 52 of the SPTAN1 gene that results in the amino acid substitution p.Trp2294_Asp2295insAspGlnLeu was identified. The observed variant is novel in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is medium, based on the effect of the protein and REVEL score. Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic/ LikelyPathogenic (Variant ID: 160028). This disorder has previously been reported in the patient affected with epilepsy (Nonoda Y et.al 2012). Based on the above evidence this variant has been classified as Likely Pathogenic according to the ACMG guidelines. -
- -
This variant is absent in population databases. There is two submission on Clinvar with pathogenic interpretation. This variant has been observed in individual(s) with clinical features of SCN2A-related conditions. -
- -
- -
- -
not provided Pathogenic:4
- -
- -
Published functional studies suggest this variant has a dominant negative effect on neurons, however additional studies are needed to validate the functional effect of this variant (Wang et al., 2018); In-frame duplication of three amino acids in a non-repeat region; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34440880, 22656320, 29337302, 29050398, 25631096) -
- -
not specified Pathogenic:1
- -
Inborn genetic diseases Pathogenic:1
The c.6908_6916dupACCAGCTGG pathogenic mutation (also known as p.D2303_L2305dup), located in coding exon 52 of the SPTAN1 gene, results from an in-frame duplication of ACCAGCTGG at nucleotide positions 6908 to 6916. This results in the duplication of 3 extra residues (DQL) between codons 2303 and 2305. This variant has been determined to be the result of a de novo mutation or germline mosaicism in one family with an isolated case of developmental delay, intellectual disability, and microcephaly. This duplication was also reported as a de novo occurrence in a 1-year-old male with West syndrome, hypomyelination of the cerebral white matter, and impaired psychomoter development (Nonoda Y et al. Brain Dev., 2013 Mar;35:280-3). The mutation occurs in the last two spectrin repeats of the SPTAN1 protein, where several in-frame duplications and deletions have been detected in patients with West syndrome (Tohyama J et al. J. Hum. Genet., 2015 Apr;60:167-73). In addition, this alteration is predicted to be deleterious by PROVEAN in silico analysis (Choi Y et al., PLoS ONE 2012; 7(10):e46688). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1
This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this variant affects SPTAN1 function (PMID: 29050398). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 160028). This variant has been observed in individual(s) with West syndrome (PMID: 22656320, 29050398). In at least one individual the variant was observed to be de novo. This variant, c.6908_6916dup, results in the insertion of 3 amino acid(s) of the SPTAN1 protein (p.Asp2303_Leu2305dup), but otherwise preserves the integrity of the reading frame. -
SPTAN1-related disorder Pathogenic:1
The SPTAN1 c.6908_6916dup9 variant is predicted to result in an in-frame duplication (p.Asp2303_Leu2305dup). This variant has been reported as a recurrent de novo change in multiple unrelated individuals affected with West syndrome with progressive brain atrophy and functional studies suggested that this variant causes aggregation of spectrin complexes in neurons via dominant-negative effects (Nonoda et al. 2013. PubMed ID: 22656320; Tohyama et al. 2015. PubMed ID: 25631096; Syrbe et al. 2017. PubMed ID: 29050398; Wang et al. 2018. PubMed ID: 29337302). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. -
Undetermined early-onset epileptic encephalopathy Other:1
Variant interpretted as Pathogenic and reported on 08-28-2019 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at